Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Imiquimod applied topically: A novel immune response modifier.

¹Departments of Dermatology and Microbiology/Immunology, The University of Texas Medical Branch at Galveston, Texas, USA.

Skin Therapy Letter

|April 12, 2001

Summary

Imiquimod is an immune response modifier approved for genital warts. It enhances the immune system to fight viral infections and tumors, showing promise for various skin conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021

Same author

Hailey-Hailey disease treated with dupilumab: a case series.

The British journal of dermatology·2021

Same author

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019

Same author

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.

The British journal of dermatology·2019

Same author

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.

The British journal of dermatology·2018

Same author

Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis.

The British journal of dermatology·2018

Area of Science:

Immunology
Dermatology
Pharmacology

Background:

Imiquimod (S-26308, R-837) is an immune response modifier approved by the US FDA in 1997.
It functions by inducing interferon alpha (IFN-alpha) and other cytokines, stimulating both innate and acquired immunity.

Purpose of the Study:

To review the efficacy of imiquimod in treating various skin conditions.
To highlight its mechanism of action in modulating the immune system.

Main Methods:

Review of clinical studies and case reports on imiquimod.
Analysis of its pharmacological activity and immune-stimulating properties.

Main Results:

Imiquimod demonstrated efficacy in Phase II studies for UV-induced skin lesions, basal cell carcinoma, and actinic keratosis.
Case studies reported benefits in treating molluscum and preventing keloids.

Conclusions:

Imiquimod is effective in treating genital and perianal warts.
Its immune-modulating properties suggest utility in viral infections, tumors, and other dermatological conditions requiring enhanced cell-mediated immunity.

Related Experiment Videos